Dr Lynn Schrader Sweeney, MD | |
701 Kerney Dr, Farmington, NM 87401-3660 | |
(505) 860-5620 | |
Not Available |
Full Name | Dr Lynn Schrader Sweeney |
---|---|
Gender | Female |
Speciality | General Practice |
Location | 701 Kerney Dr, Farmington, New Mexico |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1275901266 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | N-7571 (Arkansas) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Lynn Schrader Sweeney, MD 701 Kerney Dr, Farmington, NM 87401-3660 Ph: (505) 860-5620 | Dr Lynn Schrader Sweeney, MD 701 Kerney Dr, Farmington, NM 87401-3660 Ph: (505) 860-5620 |
News Archive
The United States Food and Drug Administration ("FDA") is cracking down on the importation of unapproved new drugs with regards to personal use. Import Alert #66-41, "Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S." ("IA 66-41") was most recently published on September 23, 2010. IA 66-41 contains a Red List, a list of importers whose products are automatically detained for FDA violations, of over 400 firms on the charge of importing misbranded unapproved new drugs. Benjamin England, founder of FDAImports.com, LLC and former FDA Compliance Officer, attorney, and Food and Drug Law expert states that "This Import Alert has been expanded to include importers and products of drugs imported strictly for personal use rather than just targeting foreign shippers, which is FDA's normal M.O."
RadNet, a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 200 fully-owned and operated outpatient imaging centers, today reported it has completed the acquisition from Presgar Imaging and affiliated entities of imaging centers in Brooklyn and Orchard Park, New York for cash consideration of $2.2 million plus the assumption of approximately $700,000 of debt.
A single dose of the drug zoledronic acid was found to inhibit the bone loss that is common in HIV-infected patients and that is increased during the first two years of treatment with antiretroviral therapy (ART).
Two enormous bulletin boards take up much of the wall space in the tiny office and laboratory. Photos of children, some just a few months old, cover each panel.
Nearly 100 members of the CIGNA Health Awareness Tour team will walk, bike and run into Blue Bell Sunday to help raise money and awareness for cancer prevention.
› Verified 6 days ago